Star’s VGA039 Eyes First Meaningful Subcutaneous Cure for von Willebrand Disease

Star Therapeutics is a clinical‑stage biotech company focused on developing novel antibody therapies in hematology and immunology. Its core program under the VEGA umbrella is VGA039 , a fully human monoclonal antibody designed to restore hemostasis by modulating Protein S , thus enhancing thrombin generation. The therapy is intended as a universal hemostatic agent for bleeding disorders, with von Willebrand Disease (VWD) as its lead indication.

In Phase 1 trials (the VIVID program), VGA039 showed nearly 100% subcutaneous bioavailability , dose‑proportional pharmacokinetics, and favorable safety in healthy volunteers — supporting its potential as a convenient subcutaneous therapy rather than intravenous regimens. The U.S. Food and Drug Administration has granted Fast Track designation to VGA039 for VWD, accelerating regulatory interactions and review prospects.

Star is advancing its clinical pipeline. A Phase 3 study — VIVID‑6 — is registered to evaluate prophylactic, subcutaneous VGA039 in adolescent and adult VWD patients over nearly 49 weeks of active dosing. The company’s hub‑and‑spoke strategy has produced spinouts like Vega Therapeutics , which specifically targets VWD and supports the development of VGA039 under the broader Star framework.

If successful, VGA039 could reduce the treatment burden for VWD patients (eliminating frequent IV infusions), deliver broader market reach (across VWD subtypes), and reinforce Star’s reputation in bleeding disorders as a clinical innovator. The Fast Track status and strong Phase 1 data make it a high‑conviction program in the bleeding disorders space.

Source: BiopharmaDive

M.A.